Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Dermalogica

Also known as: dermalogica

A professional skincare brand founded in Los Angeles in 1986 by Jane and Raymond Wurwand and owned by Unilever's Prestige division since 2015. It sells a salon-channel professional range and a consumer retail range, and runs its own postgraduate training arm, the International Dermal Institute.

Evidence status

Manufacturer-supported

Published product studies exist for MelanoPro, Pro Restore and selected formulations; a small controlled MelanoPro trial reported less post-laser pigmentation, but Dermalogica partly funded it. Every located brand-specific study was funded by, authored by or otherwise commercially connected to Dermalogica or Unilever. The brand therefore has product-level human evidence, but no independent replication, UK product trial or head-to-head professional-brand comparison was located.

What Dermalogica is, and the ranges available#

Dermalogica is a professional and consumer skincare brand launched in Los Angeles in 1986 by Jane and Raymond Wurwand. The Wurwands had established the International Dermal Institute in 1983 as a postgraduate training organisation for skin therapists; Dermalogica describes IDI as both its education arm and a participant in product research and development.[1, 7]

Unilever announced in June 2015 that it had signed an agreement to acquire Dermalogica for its Prestige division. The terms were not disclosed and the founders retained an interest. At the time, Unilever reported 2014 turnover of US$240 million and distribution in more than 80 countries; those figures came from the acquirer rather than an independent audit.[1][1]

The UK operating company is Dermalogica (UK) Limited, company number 02263856. It was incorporated in 1988, first as Gainwealthy Limited, then Dermal Products (U.K.) Limited, taking its current name in 1994. Companies House records Unilever Overseas Holdings Limited as its sole person with significant control, with more than 75% of shares and voting rights and the power to appoint or remove directors.[2][2]

The range divides commercially into retail products and “Dermalogica Professional Products”. Retail collections are sold directly to consumers and through numerous authorised online sellers. Professional products are supplied through trade accounts under a selective distribution agreement. That contractual distinction controls channels; it does not make one category a medicine or establish greater clinical efficacy.[10, 11]

Use of Dermalogica in aesthetic practice#

In Great Britain, Dermalogica skincare and professional peel products are cosmetics under assimilated Regulation (EC) No 1223/2009. The law requires a Responsible Person, safety assessment, Product Information File, notification and compliant labelling. It does not approve efficacy and it does not license the practitioner applying a product. Northern Ireland follows the EU cosmetics regime, so GB and NI compliance should not be collapsed into one statement.[8]

The professional account agreement distinguishes retail from treatment-room products and sets conditions for websites, social media, salons and other sales channels. Those are commercial terms between Dermalogica and the account. They do not replace the clinic's own competence, insurance, consultation, consent or product-specific records.[10]

The International Dermal Institute offers courses described as CIBTAC-endorsed Level 4 awards in microneedling and skin peels. CIBTAC distinguishes endorsement of another organisation's CPD course from its own regulated qualifications on the Regulated Qualifications Framework. The specific awards could not be confirmed on Ofqual's register; their exact status therefore requires a qualification number, not an inference from the words “Level 4”.[12, 13]

England's 2023 licensing consultation placed microneedling and epidermal-depth peels among indicative green-tier examples, deeper peels in amber and phenol peels in red. These placements remain proposals, not current law, and the 2025 government response did not allocate procedures to tiers.[9]

Contraindications and cautions#

Dermalogica is a brand portfolio rather than one intervention. Contraindications depend on the exact formula, concentration, pH, intended use and procedure, together with the client's medicines, diagnoses, barrier status and planned treatment. The current manufacturer directions for the named product govern; a brand-wide contraindication list would be unsafe.

Professional peel systems and post-procedure products require separate screening. An ingredient tolerated in a retail moisturiser does not establish suitability in a peel, and a product sold for use around microneedling or laser treatment does not itself establish that the underlying procedure is appropriate.

The MelanoPro trial concerned a multi-acid and retinoid system around fractional carbon-dioxide resurfacing in Fitzpatrick III–V skin. The formula was reported from a Dermalogica document rather than an independent chemical assay and included azelaic acid 10%, niacinamide 5%, glycolic acid 3.5%, lactic acid 2.7%, tranexamic acid 2%, retinol 0.25–0.3% and salicylic acid 0.1%. Each component and the procedure create screening considerations that cannot be reduced to the brand name.[3]

Clinical uses and the evidence behind them#

MelanoPro around fractional carbon-dioxide resurfacing

The most controlled Dermalogica product study without company-employed authors randomised 30 people and analysed 29. Participants were aged 17–45, had Fitzpatrick III–V skin and grade 4B atrophic acne scars, and underwent fractional carbon-dioxide laser resurfacing. Fifteen used the MelanoPro system before and after resurfacing and 14 received no peel. At week six, median PIHASI was 0.0 (IQR 0.0–0.2) with MelanoPro and 0.2 (IQR 0.2–0.4) without it (p=0.015); any measurable pigmentation occurred in six of 15 versus 11 of 14. Re-epithelialisation time and scar improvement did not differ.[3]

The trial was evaluator-blinded but single-centre, used no vehicle or active peel comparator and ended at six weeks. It was partially funded by Dermalogica. A later correction aligned the funding wording and removed the proprietary name from eight places because it could be perceived as overly commercial. The article declared no conflicts despite acknowledging the funding.[3]

The abstract says no adverse events were reported, while the paper's body records two cases of persistent desquamation, pruritus and discomfort in the peel arm, resolving after the product was paused. The body text is the fuller safety account.[3]

MelanoPro for hyperpigmentation

A company-led paper combined melanocyte experiments with a six-week, single-arm assessment in 33 women aged 30–55 at a claims-testing laboratory in Valencia. It reported improvements in dark-spot measures, homogeneity, contrast, brightness and roughness, but the human study had no described comparator, randomisation or blinding and did not publish the effect sizes in its abstract.[5]

Its cell experiment also requires careful separation from human evidence. Only two concentrations were tested for melanin, the lower performed better, and the higher was not statistically significant. Cell viability fell at overlapping concentrations. The results do not establish a clean concentration-response or a clinical mechanism. All seven authors were Dermalogica or Unilever employees or had received Dermalogica honoraria.[5]

Pro Restore after microneedling

A randomised split-face study in 32 healthy women aged 30–70 compared a multiple-active, omega-3-rich Dermalogica formulation with a hyaluronic-acid control serum after microneedling. Expert grading favoured the multi-active product for erythema, luminosity and texture over 28 days. The comparator was not a matched vehicle, so the result belongs to the complete formulation rather than specifically to omega-3 fatty acids. Five of eight authors worked for Dermalogica, two for Unilever and the remaining author declared Dermalogica honoraria.[4]

A separate mechanistic narrative review drew on published literature and unpublished Unilever data, was written and funded entirely by Unilever, and tested no Dermalogica product. It supports a biological rationale for DHA and EPA, not independent proof of Pro Restore.[6]i

Other retail and professional products

The independent literature located outside those company-linked papers only mentions Dermalogica incidentally. A 2014 audit of 52 acne moisturisers listed Active Moist by declared ingredients but did not test it. No systematic review, brand comparison or UK Dermalogica product trial was located.[14]

Selecting Dermalogica products#

Selection is product-specific. The useful questions are the exact formulation and intended use, whether the marketed finished product was tested, who was studied, the comparator, body site, duration, outcome and commercial involvement. Ingredient evidence can explain plausibility but cannot validate a different Dermalogica formula.

Evidence is strongest when it names a finished product and carries an appropriate comparator. MelanoPro has a small controlled post-laser trial against no peel; Pro Restore has a split-face comparison against hyaluronic acid; the company MelanoPro pigmentation study is single-arm; other performance figures on the professional website are not linked to sufficient public methods for appraisal.[3, 4, 5, 12]

Channel choice is separate. The retail line is openly sold through Dermalogica's own site and 36 listed online retailers, including general beauty sellers. Professional-only supply refers to designated products under the trade agreement, not to the whole brand.[10, 11]

For peels, microneedling adjuncts and all post-procedure use, the current Dermalogica instructions and the procedure or device manufacturer's directions govern. Skinipedia does not publish a substitute protocol.

Adverse effects and their management#

Product irritation

The controlled MelanoPro study recorded two of 15 peel-arm participants with mild-to-moderate persistent desquamation, itching and discomfort. The study paused and later reintroduced the product; that is a report of the named study procedure, not a generic protocol.[3]

Other Dermalogica products contain materially different active systems. Irritation, allergy, photosensitivity and barrier disruption must therefore be assessed from the named ingredient list, concentration, product directions and exposure rather than extrapolated across the range.

Procedure-related effects

When a Dermalogica product is used around microneedling, laser or a peel, adverse effects can belong to the product, the procedure, their timing or their combination. Documentation should preserve each exposure separately. A favourable appearance endpoint at four or six weeks does not establish long-term safety, and the small studies cannot detect rare harms.[3, 4, 5]

Unexpected or persistent reactions

Persistent erythema, swelling, blistering, escalating pain, infection, pigment change or symptoms outside the product's expected pattern require the product and associated procedure to be stopped and assessed under the clinic's current escalation policy and manufacturer directions.

Referral and scope boundaries#

Dermalogica products do not authorise treatment of a medical diagnosis. Acne requiring medical management, suspected dermatitis, infection, unexplained or changing pigmentation, a poor-healing response, or a reaction exceeding the practitioner's competence requires referral to an appropriate clinician.

A Dermalogica or IDI certificate confirms completion of that brand's training. It is not, by itself, evidence of an Ofqual-regulated qualification, statutory licence or independent competence assessment. Where an insurer, employer or future licensing scheme specifies a qualification, the course title and qualification number need to meet that requirement.[12, 13]

Mechanism of action#

Dermalogica's products use established cosmetic ingredient families, but a mechanism belongs to the specific composition and delivery system. MelanoPro combines azelaic, tranexamic, hydroxy-acid, retinoid and niacinamide components; Pro Restore is a multiple-active formulation containing omega-3 fatty acids. No study isolates every component's contribution.[3, 4, 5, 6]

Ingredient mechanisms are covered in azelaic acid, tranexamic acid, retinoids and the relevant acid entries. A mechanistic rationale is not an efficacy result for the finished brand product.

Conflict-of-interest reporting across the Dermalogica-linked literature is inconsistent: a wholly Unilever-authored, Unilever-copyrighted review states that 'no competing interest exists', and the Dermalogica-funded peel trial states 'The authors declare no conflicts of interest' while acknowledging Dermalogica funding in the same paper.[3, 6]

Commonly misstated claims#

“Dermalogica is professional-only”

The UK retail range is sold directly to consumers with public pricing and through 36 authorised online retailers. Designated professional products remain trade-gated under the distribution agreement.[10][11]

Supported statement: Dermalogica has separate consumer-retail and professional-product channels.

“Its products are backed by independent clinical studies”

The studies are published and the brand names them, but the two papers it promotes most directly were written entirely by Dermalogica or Unilever employees plus one author receiving Dermalogica honoraria. The controlled MelanoPro laser trial had no company-employed author but was partially funded by Dermalogica.[3, 4, 5, 12]

Supported statement: selected Dermalogica products have peer-reviewed, commercially connected studies whose findings must be read at product level.

“The IDI Level 4 awards are Ofqual-regulated qualifications”

Dermalogica uses both “endorsed” and “regulated” language, while CIBTAC describes endorsement as a quality mark for another organisation's CPD scheme, separate from its own regulated qualifications. The exact awards were not confirmed on the Ofqual register.[12, 13]

Supported statement: the courses are CIBTAC-endorsed; regulated status should be confirmed by the exact qualification number.

“A large global brand necessarily has a strong independent evidence base”

Unilever reported US$240 million turnover and distribution in more than 80 countries at acquisition, but only a small, commercially connected product literature was located.[1, 3, 4, 5, 6, 14]

Supported statement: corporate scale and product evidence are separate measures.

Areas of remaining uncertainty#

  • MelanoPro's post-laser pigmentation result ends at six weeks and has no active comparator; this prevents claims about durability or superiority to another regimen.
  • Pro Restore was compared with plain hyaluronic acid rather than a matched vehicle; this prevents attribution of the result specifically to omega-3 fatty acids.
  • The exact status of IDI's CIBTAC-endorsed Level 4 awards was not confirmed on Ofqual's register; this means a practitioner needs the qualification number before relying on “regulated” wording.
  • Dermalogica and IDI have published the “100,000 therapists” figure in differing annual and cumulative forms without audit; this prevents a reliable scale claim beyond the company's current wording.[7]
  • No head-to-head brand trial or UK Dermalogica product trial was located; this prevents evidence-based claims of brand superiority or direct transfer to UK practice.[no source found]

No peer-reviewed evaluation exists of whether International Dermal Institute training changes practitioner competence, treatment outcomes or complication rates.[no source found]

Frequently asked questions#

Is Dermalogica owned by its founders?

No. Unilever announced the acquisition in 2015, and Companies House records a Unilever company as the UK entity's sole person with significant control. The founders retained an interest.[1, 2]

Are Dermalogica products medical-grade?

“Medical-grade” is not the legal category. In GB, the skincare and peel products are cosmetics subject to cosmetic safety, notification and labelling rules; efficacy is not pre-approved.[8]

Can consumers buy Dermalogica online?

Yes. The brand sells its retail lines directly and through authorised e-tailers. Certain professional products remain subject to trade distribution terms.[10, 11]

Are its studies independent?

The located studies are commercially connected through authorship, funding or honoraria. That does not erase their findings; it means the connection travels with any claim.[3, 4, 5, 6]

Does IDI training replace a regulated qualification?

No. Product and protocol training may support competence, but the exact course must be checked against any qualification, insurance or licensing requirement.[12, 13]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Unilever. 'Unilever to acquire Dermalogica skincare.' Press release, London/Rotterdam, 24 June 2015. Read via the Internet Archive capture of 27 June 2015.Tier 4Supports: Primary corporate announcement. Verbatim: 'Unilever announced today that it has signed an agreement to acquire Dermalogica, the world's number one professional skin care brand.' 'The leading skincare brand in professional salons and spas worldwide, Dermalogica was launched in 1986 in Los Angeles by Jane and Raymond Wurwand; following the earlier creation of The International Dermal Institute in 1983, the first of its kind to provide training to licenced skin therapists.' 'Dermalogica is currently sold in over 80 countries.' 'The brand is sold in locations where there is a licensed skin care professional who can provide advice on how to address skin problems such as hyperpigmentation, acne, ageing, and sensitive skin.' 'The brand, which had a turnover of US$240m in 2014, will be incorporated into Unilever's Prestige division, which is exclusively dedicated to select distribution and premium personal care brands. Terms of the deal were not disclosed.' Polman quote confirms 'I am pleased that Jane and Raymond have retained an interest in the company and will continue to work with us to grow the brand.' The release also states 'The transaction is subject to customary regulatory approvals.' Every quotation above was re-checked word for word against the archived page on 2 August 2026. Scope limits: an acquirer's announcement of its own deal; the US$240m turnover and 80-country figures are company-supplied and unaudited in this document; it records signing subject to regulatory approval, not completion, and no price was disclosed.Funding / interest: Written and published by Unilever plc about its own acquisition. All figures are Unilever/Dermalogica-supplied.
  2. Companies House. DERMALOGICA (UK) LIMITED, company number 02263856 — company overview, previous names, officers and persons with significant control. Accessed 1 August 2026.Tier 1Supports: Statutory UK register. Status Active; private limited company; incorporated 1 June 1988. Previous names: GAINWEALTHY LIMITED (01 Jun 1988 – 31 Jan 1989), then DERMAL PRODUCTS (U.K.) LIMITED (31 Jan 1989 – 21 Jul 1994), then the current name from 21 July 1994. Registered office: First Floor, Q4 The Square, Randalls Way, Leatherhead, Surrey KT22 7TW. Nature of business SIC 46450 — 'Wholesale of perfume and cosmetics'. Last accounts made up to 31 December 2024; next accounts to 31 December 2025 due by 30 September 2026. Last confirmation statement 23 April 2026. Officers: 20 officers / 18 resignations. Persons with significant control: one active PSC, 'Unilever Overseas Holdings Limited', registration number 174036, correspondence address Unilever House, 100 Victoria Embankment, London EC4Y 0DY, notified 6 April 2016, nature of control 'Ownership of shares – 75% or more', 'Ownership of voting rights - 75% or more', 'Right to appoint or remove directors'. Scope limits: Companies House states it 'does not check the accuracy of the information filed'; the 6 April 2016 notification date reflects the commencement of the PSC regime, not the date control was acquired; the register shows the SIC code as wholesale, which does not describe the training activity.
  3. Hang X, Lim DS. A Novel Peel to Prevent Post-Inflammatory Hyperpigmentation After CO2 Resurfacing for Acne Scars. J Cosmet Dermatol. 2025 Aug;24(8):e70366. PMID 40736045; PMCID PMC12309148. Correction: J Cosmet Dermatol. 2025 Sep;24(9):e70469. PMID 40971317.Tier 2Supports: The only clinical study of a Dermalogica product located with no company-employed authors (QIMR Berghofer and Cutis Clinic, Queensland, Australia; research conducted at Cutis Clinic, the second author's own clinic). Design, verbatim: 'This was a prospective, single-centre, randomized, controlled, evaluator-blinded study conducted in accordance with the Declaration of Helsinki', 'supervised by a Fellow of the Australasian College of Dermatologists (FACD)'. Intervention: 'a MelanoPro Peel System (Dermalogica Pro, Carson, CA, USA)' from 15 days pre-laser and restarted day 7 post-laser for 4 weeks, versus 'no peel'. 30 recruited and randomised, one control dropout, 29 analysed (peel n=15, control n=14). Population: Fitzpatrick III-V, age 17-45, Grade 4B atrophic acne scars (Goodman and Baron), fractional eCO2 Plus laser, analysis restricted to the cheeks. Both arms received identical standardised aftercare (Cetaphil cleanser, white soft paraffin, physical SPF 50+ twice daily, doxycycline 50 mg for 7 days). Blinding: the primary dermatologist was blinded to allocation and scored standardised photographs. Results at week 6: median PIHASI 0.0 (IQR 0.0-0.2) peel vs 0.2 (IQR 0.2-0.4) control; Mann-Whitney U z = 2.427, p = 0.015 (exact p = 0.016). Patient-level Tables 2 and 3 show a responder split the abstract does not report: 6 of 15 in the peel arm recorded any PIH at all versus 11 of 14 controls. Re-epithelialisation day 6.4 (peel) vs day 6.2 (control). Scar reduction 1.27 +/- 0.59 vs 1.36 +/- 0.63, p = 0.694 (no significant difference). SAFETY — the abstract states 'No adverse events were reported', but Methods section 2.9.3 of the same paper reports 'Two cases of mild to moderate skin irritation, characterized by persistent desquamation, pruritus, and mild discomfort', at weeks 2-3 and weeks 3-4, resolving after the peel was stopped for four days and reintroduced from day five; no prolonged erythema, persistent irritation or allergic reactions occurred. The abstract's safety line therefore contradicts the paper's own body text and should not be quoted alone. Table 5 reports MelanoPro composition, cited to a Dermalogica Pro document (reference 30), not to independent analysis: azelaic acid 10%, tranexamic acid 2%, salicylic acid 0.1%, glycolic 3.5% / lactic 2.7%, retinol 0.25-0.3%, niacinamide 5%, acetyl hexapeptide-1 (no concentration given). Scope limits: single centre, n=29, no vehicle or sham comparator (the control arm received no peel), 6-week endpoint only, Australian cohort, no active comparator; the authors state 'further studies with larger cohorts are needed to validate its long-term efficacy'.Funding / interest: Acknowledgements state 'This study was partially funded by Dermalogica. The sponsor had no role in study design, data collection, analysis, or manuscript preparation.' The Conflicts of Interest statement nonetheless reads 'The authors declare no conflicts of interest.' The article as published also carries the line 'Funding: This work was supported by Dermatologica.' A Correction (J Cosmet Dermatol 2025;24(9):e70469, PMID 40971317) was published on 19 September 2025 doing TWO things, not one: (i) aligning the PDF funding statement from 'This work was supported by Dermalogica' to 'This work was partially funded by Dermalogica'; and (ii) at the authors' request, replacing the proprietary product name 'MelanoPro' with the neutral descriptor 'novel peel system' at eight named locations throughout the article, because 'the use of the proprietary product name could be perceived as overly commercial'. The correction states these changes 'do not affect the scientific content or conclusions'.
  4. Wong R, Murphy A, Lira M, Sichmann MGO, Kim AR, Saechee VD, Hermanson KD, Hawkins SS. Microneedling with a Novel, n-3-PUFA-Rich Formulation Accelerates Inflammation Resolution to Improve Skin Recovery Outcomes in Adults with Healthy Skin. Dermatol Ther (Heidelb). 2023 Dec;13(12):3057-3069. PMID 37833618; PMCID PMC10689607.Tier 2Supports: Randomised, controlled, split-face study; 32 healthy female participants aged 30-70 years; 4 weeks following microneedling. Intervention: a novel multiple-active formulation containing omega-3 (n-3) polyunsaturated fatty acids, versus a hyaluronic acid control serum under a conventional microneedling protocol. Assessment by blinded clinical photography and expert evaluation at baseline, 1 hour, 1 day, 7 days and 28 days post-treatment, with VISIA-CR imaging. Result: 'Significantly greater improvements in expert-assessed erythema, luminosity and skin texture were reported following application of the novel multiple-active-ingredient formulation than the hyaluronic acid control serum.' No effect sizes, p-values or confidence intervals are given in the abstract. Scope limits: all-female, healthy-skin cohort; 28-day maximum follow-up; appearance endpoints assessed by expert grading rather than any clinical outcome; the comparator is a plain HA serum, not a matched vehicle, so the multi-active formulation cannot be attributed to its n-3 PUFA content; the study is the published version of the white paper the brand markets as 'Pro Restore'.Funding / interest: Verified against the published COI statement: 'Russell Wong has received honoraria from Dermalogica, LLC. Angela Murphy, Monica Lira, Mariangela G. de O. Sichmann, Alexis R. Kim and Veronica D. Saechee are employees of Dermalogica, LLC. Kevin D. Hermanson and Stacy S. Hawkins are employees of Unilever Research and Development.' So five of eight authors are Dermalogica employees, two are Unilever employees, and the eighth and lead author — affiliated to Rejuvenation Medical Group, Edmonton, Canada, not to the company — declares Dermalogica honoraria. No author is free of a commercial interest in the product tested.
  5. Wong R, Sichmann MGO, Sun J, Kim AR, Bianchini RJ, Hermanson KD, Chabert L. In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction. Dermatol Ther (Heidelb). 2025 May;15(5):1209-1225. PMID 40254690; PMCID PMC12033157.Tier 3Supports: Two-part company study of the MelanoPro peel system (masque plus moisturiser). IN VITRO — the abstract claims 'concentration-dependent inhibition of melanin accumulation' by the moisturiser against UVA-induced melanin in human melanocytes, but the paper's own results do not show a dose-response: only two concentrations were tested for melanin, and the LOWER one (0.0001%) gave a 23.0% reduction (95% CI 3.2 to 42.8; p = 0.0206) while the HIGHER one (0.001%) gave 13.8% and did not reach significance (p = 0.2117). The MTT viability assay in the same paper found the moisturiser cytostatic from 0.0003% upward (viability -15.2%, p = 0.0049; -53.6% at 0.001%; -59.0% at 0.003%), so reduced melanin at these dilutions is not cleanly separable from reduced cell activity. This is cell culture, not human data. IN VIVO — the abstract calls it 'a single-center, controlled study', but no comparator arm is described anywhere in the paper: the only controls reported are the in-vitro cell controls, and the human part is a single-arm before-and-after assessment run March to June 2023 at Dermaclaim Lab S.L., Valencia, Spain, in 33 healthy female participants aged 30-55 years with moderate-to-severe hyperpigmentation over a 6-week treatment period, assessed by clinical photography, 3D skin topography and clinical expert evaluation at baseline and 6 weeks, plus a self-evaluation questionnaire. Reported 'significant reductions in dark spot number, area, and perimeter' at week 6 with improvements in skin homogeneity, contrast, brightness, skin tone and roughness. No numeric effect sizes or p-values in the abstract. The authors themselves write that 'Comparative studies using a split-face design could help to clarify the system's distinct effects compared with conventional treatments, while blinded study designs would reduce bias in subjective assessments.' Scope limits: no randomisation, no comparator arm, no blinding; all-female, 30-55, otherwise healthy skin; 6 weeks; every endpoint is an appearance measure; ethical approval was granted by Dermaclaim Lab S.L. itself, a contract claims-testing laboratory, rather than by a university or NHS research ethics committee.Funding / interest: Verified against the published COI statement: 'Russell Wong has received honoraria from Dermalogica, LLC. Mariangela G. de O. Sichmann and Kevin D. Hermanson are employees of Unilever Research & Development. James Sun, Alexis R. Kim, Robert J. Bianchini, and Louis Chabert are employees of Dermalogica, LLC.' Four of seven authors are Dermalogica employees, two are Unilever employees, and the lead author declares Dermalogica honoraria. No author is free of a commercial interest in the product tested.
  6. Nip J, Hermanson K, Lee JM. n-3 PUFAs docosahexaenoic acid and eicosapentaenoic acid are effective natural pro-resolution ingredients for topical skin applications. Int J Cosmet Sci. 2025 Oct;47(5):820-826. PMID 40274542; PMCID PMC12489883.Tier 4Supports: Narrative review supplying the mechanistic rationale behind Dermalogica's post-procedure n-3 PUFA line. Stated method, verbatim: 'A review of the literature and Unilever data on DHA/EPA pro-resolution skin benefits. PubMed/MEDLINE, Google search of external literature as well as Unilever data relating to skin inflammation, pro-resolution, and the role of DHA and EPA.' Conclusion: 'DHA and EPA, and their derived specialized pro-resolving mediators (SPMs), can attenuate the skin inflammatory response induced by various stressors and maintain skin health.' Scope limits: not a systematic review — no protocol, no search dates, no inclusion criteria, no risk-of-bias assessment and no quantitative synthesis; it explicitly incorporates unpublished internal company data that a reader cannot check; it reviews an ingredient class, not any Dermalogica product.Funding / interest: All three authors are employees of Unilever Research and Development, Trumbull, Connecticut, and the corresponding address is john.nip@unilever.com. Copyright is held as '© 2025 Unilever'. The funding statement reads: 'This work was funded by Unilever Research and Development. Unilever provided support in the form of salaries for authors (JN, KH and JML).' Despite that, the published conflict-of-interest statement immediately below it reads: 'The authors declare that no competing interest exists.'
  7. International Dermal Institute. Homepage. dermalinstitute.com. Accessed 1 August 2026.Tier 4Supports: Brand-published description of the training arm. Verbatim: Jane Wurwand 'is the Co-Founder and Chief Visionary of Dermalogica and The International Dermal Institute'; 'Today, Dermalogica is the number one choice of skin professionals worldwide, known for its #1 selling powder exfoliant and training more than 100,000 skin therapists per year.' On the R&D role: 'The International Dermal Institute (IDI) is a leader in postgraduate skin and body therapy education and plays a key role in the research and development of Dermalogica products. Its dedicated team of scientists and staff focus on creating innovative, high-quality formulations that support skin health. IDI ensures that all products meet rigorous standards, avoiding common irritants and breakout-causing ingredients, and contributes directly to the development of Dermalogica's professional and retail lines.' Headquarters given as 1535 Beachey Place, Carson, CA 90746. Scope limits: entirely self-reported and unaudited; the '100,000 skin therapists per year' figure is stated as annual throughput and is not reconcilable with cumulative alumni figures published elsewhere by the group; no accreditation body is named on the page.Funding / interest: Published by the International Dermal Institute, the training and R&D division of Dermalogica (Unilever). Every figure is self-reported.
  8. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast), as assimilated direct legislation in Great Britain. legislation.gov.uk. Accessed 1 August 2026.Tier 1Supports: The governing law for every Dermalogica product placed on the GB market, professional and retail alike. Article 4 establishes the Responsible Person accountable for compliance; Article 10 requires a documented safety assessment (the Cosmetic Product Safety Report) covering composition, stability and toxicological profile before market placement; Article 11 requires a Product Information File; Article 13 requires notification to the competent authority before placing on the market; Article 19 governs mandatory labelling and ingredient disclosure. Retained on legislation.gov.uk with amendments applied since IP completion day (31 December 2020). Scope limits: cosmetics law regulates safety, composition, labelling and notification — it does not assess or approve efficacy, and it does not regulate who may apply a product, in what setting, or what training they hold. Post-Brexit EU amendments to the Annexes do not automatically flow into GB law; Northern Ireland follows the EU text under separate arrangements.
  9. Department of Health and Social Care. 'The licensing of non-surgical cosmetic procedures in England.' Consultation document, open 2 September to 28 October 2023; government response published 7 August 2025.Tier 1Supports: The proposed three-tier model, verbatim. Green: 'procedures with the lowest risk of complications. All practitioners are eligible to perform licensed procedures where they meet agreed standards.' Amber: 'procedures with medium risk of complications. Non-healthcare professionals must be licensed and have relevant oversight by a named regulated healthcare professional.' Red: 'procedures with the highest risk of complications', to be brought into CQC regulation. Indicative placements relevant to Dermalogica's professional protocols: microneedling in green; 'chemical peels that involve destruction only into viable epidermis (the outermost layer of the skin)' in green; 'medium depth peels that involve full thickness destruction of entire epidermis into upper dermis' in amber; 'deeper chemical peels such as phenol peels' in red. The document states, verbatim: 'Please note, the procedures listed are indicative examples only and may change based on the outcome of this consultation'. The red-tier definition continues: 'In line with the proposal on CQC regulation of cosmetic procedures outlined above, bringing specified high-risk procedures into CQC regulation, so that they fall outside of the scope of the licensing scheme.' Consultation opened 9am on 2 September 2023 and closed 11:59pm on 28 October 2023; status now 'Concluded'. Scope limits: this is a PROPOSAL. No licensing scheme is in force. Implementation requires secondary legislation and Parliamentary approval. The tier placements come from the 2023 consultation document only — verified 2 August 2026, the government response of 7 August 2025 does NOT assign individual procedures to green/amber/red tiers; it sets out a two-strand approach (CQC regulation of specified high-risk procedures, local authority licensing for lower-risk ones) and states that further work is needed to determine classification. England only.
  10. Dermalogica PRO UK. 'Selective Distribution Agreement.' Published trade contract template, pro.dermalogica.co.uk. Accessed 1 August 2026.Tier 4Supports: The brand's own published trade contract. Parties: '(1) Dermalogica (UK) Limited, registered in England and Wales with company number: 02263856'. Verbatim on the channel model: 'Dermalogica's products have become a professional skincare brand that distributes under a selective distribution system to maintain the high-end brand profile.' 'To ensure a customer experience that is consistent with the Dermalogica brand, an account selling Dermalogica products through multichannel retail technologies and tools (website, mobile, social media, salon or shop) must meet several requirements. These requirements apply to all channels and regions in which the Distributor operates and are applied uniformly.' Defines two distinct goods categories: 'Dermalogica Professional Products: means the goods (or any part of them) set out in the Order which are designated by Dermalogica as professional products' and 'Dermalogica Retail Products ... designated by Dermalogica as retail products'. Trade ordering and training access run through a B2B account at myaccount.dermalogica.co.uk. Description of the product base: 'Its formulas are free of artificial colours and fragrances, mineral oil, lanolin, alcohol, parabens and microplastics ... gluten-free and vegan.' Scope limits: this is contract text, not law; the ingredient exclusions are marketing assertions, not verified analysis; and the registered office in the template (The Manser Building, Thorncroft Drive, Dorking Road, Leatherhead, KT22 8JB) does not match the current Companies House registered office, so the template is not fully current.Funding / interest: Published by Dermalogica (UK) Limited, a Unilever subsidiary, as its own commercial terms.
  11. Dermalogica UK. Consumer storefront and 'Authorised Retailers' listing, dermalogica.co.uk. Accessed 1 August 2026.Tier 4Supports: Direct evidence of the consumer channel in the UK. dermalogica.co.uk is a full transactional storefront with public pricing (e.g. 'Active Moist Moisturiser £45.00'; 'phyto nature e2 regenerating daily exosome leave-on treatment £148.00'), promotional bundles and 'FAST + FREE delivery on all orders over £80', with no professional verification at any point. The published product-range taxonomy is: daily skin health, dynamic skin, multivitamin power, biolumin-c, ultracalming, active clearing, phyto nature, powerbright, clear start. The PowerBright collection page describes the hyperpigmentation range (Dark Spot Serum, Dark Spot Peel, Moisturizer SPF 50, Overnight Cream). The Authorised Retailers page lists 36 authorised UK online sellers, including general beauty e-tailers with no professional gate (allbeauty.com, cultbeauty.co.uk, lookfantastic.com, escentual.com, brandalley.co.uk, justmylook.com, facethefuture.co.uk) alongside salon and clinic sites, while stating 'Dermalogica products are guaranteed when recommended by a professional skin therapist' and naming unauthorised sellers separately. Scope limits: a snapshot of one date; prices and retailer lists change; the page does not state which SKUs are restricted to trade accounts.Funding / interest: Dermalogica (UK) Limited's own e-commerce and channel-policy pages.
  12. Dermalogica PRO UK. 'Clinical Trials & Proven Results' and 'CIBTAC Endorsed Level 4 Qualifications', pro.dermalogica.co.uk. Accessed 1 August 2026.Tier 4Supports: The brand's own evidence and education claims, as marketed to UK practitioners; page text re-fetched and checked line by line on 2 August 2026. Clinical-results page, verbatim: 'We continuously invest in independent clinical studies to ensure our products achieve demonstrable, measurable results for skin health'; 'Our clinical studies meet the following standards: a minimum of 30 participants, formulations applied under dermatological supervision in realistic conditions, and all results measured objectively with imaging techniques and instrumental skin analysis.' Named methods are 'objective in-vivo', 'subjective in-vivo' and 'objective in-vitro'. IMPORTANT CORRECTION TO AN EARLIER READING OF THIS PAGE: the outputs are labelled 'white papers', but the white-paper library does identify the peer-reviewed work. It lists 'Melanopro White Paper: In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction. Authors: Russell Wong, Mariangela G. de O. Sichmann, James Sun, Alexis R. Kim, Robert J. Bianchini, Kevin D. Hermanson, Louis Chabert. Published online: 20th April 2025' and 'Pro Restore White Paper: Microneedling with a Novel, n-3-PUFA-Rich Formulation Accelerates Inflammation Resolution to Improve Skin Recovery Outcomes in Adults with Healthy Skin' with the full Wong et al. author list — those are the verbatim titles and author lists of PMID 40254690 and PMID 37833618, and the Pro Restore author names are hyperlinked to PubMed author queries carrying cauthor_id=37833618. The page does not give journal names, DOIs or PMIDs, and hosts the papers as self-branded PDFs. So the accurate criticism is not that the evidence is unpublished or unnamed — it is that the two studies the page presents under the banner 'independent clinical studies' are the two in which five of eight and four of seven authors respectively are Dermalogica employees, the rest Unilever employees, and the sole non-employee author declares Dermalogica honoraria. Other figures presented on the clinical-results page: Exo Booster '86% greater reduction in wrinkle appearance compared to treatment alone (21 days post procedure)' and '46% increase in skin resilience compared to treatment alone (21 days post procedure)', plus the unfalsifiable 'Exo Booster is superior to human exosomes for aesthetic procedures'; Phyto Nature e2 'After 8 weeks skin's natural regeneration improved by 86% and giving 6 years back', in 32 volunteers over 8 weeks. On the PRO homepage (not the clinical-results page): 'products backed by independent clinical studies' and 'NEW: FutureCode Booster. Our latest innovation is clinically shown to help transform the appearance of skin in as few as 7 days.' Education page (pro.dermalogica.co.uk/education/level-4-qualifications/), verbatim: the page headings read 'CIBTAC Endorsed level 4 qualifications' and 'level 4 regulated qualifications' one after the other; 'Access CIBTAC endorsed Level 4 qualifications in Microneedling and Skin Peeling Treatments. Hosted by The International Dermal Institute in partnership with Dermalogica.'; 'A Level 4 qualification in Microneedling and Chemical Peels is an advanced, regulated vocational qualification aligned to National Occupational Standards (NOS).' Two awards offered — CIBTAC Level 4 Award in Microneedling Treatments and CIBTAC Level 4 Award in Skin Peels — 'Both require a minimum of 120 hours, completed over the course of 12 weeks', with multiple practical case studies and 'a final, in-person, assessment'; no price is published, only an enquiry form. Scope limits: marketing copy; the linked white-paper PDFs were not downloaded and appraised in their own right; the Exo Booster, Phyto Nature e2 and FutureCode figures have no published participant counts, comparators or statistics attached to them on the page; and the education page uses 'endorsed' and 'regulated' as headings on the same screen without distinguishing them.Funding / interest: Dermalogica (UK) Limited marketing pages promoting its own products and paid training courses.
  13. CIBTAC (Confederation of International Beauty Therapy and Cosmetology). Qualifications page, including 'Internationally Recognised', 'Other Recognised Qualifications' and the endorsement paragraph. cibtac.com. Accessed 2 August 2026.Tier 4Supports: The awarding body's own wording, which is the check on Dermalogica's. CIBTAC's page distinguishes THREE things, and they must not be run together. (1) Regulated qualifications: 'CIBTAC is regulated as an awarding organisation by OFQUAL, a UK government agency. This means that all our regulated qualifications appear on the UK framework and carry a Level ... Our qualifications are also broken down into Awards, Certificates and Diplomas.' CIBTAC's Ofqual registration number is RN5124. (2) 'Bespoke' qualifications: 'CIBTAC also has a range of "bespoke" qualifications which do not appear on the framework. These are respected and insurable industry qualifications that have been in existence for many years, before the start of an education framework in the UK in vocational subjects such as beauty therapy. Over the course of the next year, these will start to be moved across onto the RQF, or phased out because a similar qualification already sits on the framework.' (3) ENDORSEMENT, which is what Dermalogica's awards carry and is a separate thing again: 'In addition to our own qualifications, CIBTAC endorses training schemes in innovative continuous professional development (CPD) subjects that offer an excellent quality progression opportunity to learn a subject not already offered by CIBTAC or that bring a substantial benefit to the sector. After a comprehensive review of the quality of these courses CIBTAC places its prestigious endorsement mark to the certificates, which are produced by us in our UK head office.' Endorsement is therefore a quality mark CIBTAC applies to somebody else's CPD training scheme — not one of CIBTAC's own qualifications, regulated or bespoke, and not an Ofqual-regulated award on the RQF. Scope limits: this is the awarding body describing its own product lines, not a regulator's determination; the page does not name the Dermalogica or International Dermal Institute awards, so the mapping from 'CIBTAC endorsed Level 4 Award' to 'not on the RQF' remains an inference from CIBTAC's general wording rather than a confirmed register entry.Funding / interest: Published by CIBTAC, a commercial awarding organisation that sells both endorsed and regulated qualifications.
  14. Chularojanamontri L, Tuchinda P, Kulthanan K, Pongparit K. Moisturizers for Acne: What are their Constituents? J Clin Aesthet Dermatol. 2014 May;7(5):36-44. PMID 24847408; PMCID PMC4025519.Tier 4Supports: An independent, non-industry ingredient audit — and the clearest illustration of how the independent literature actually engages with Dermalogica. Four dermatologists at Siriraj Hospital, Mahidol University, Bangkok surveyed 'Fifty-two moisturizers for acne' by declared ingredients. 'Dermalogica Active Moist Moisturizer (Dermalogica)' appears as product 36 in the surveyed list. Across the whole sample: 92% of products had anti-inflammatory properties; salicylic acid, benzoyl peroxide and retinol were present in 35%, 10% and 8% of the anti-inflammatory products respectively; more than half contained dimethicone and/or glycerin. Scope limits: this is a label and formulation audit, not a clinical trial. No product, including the Dermalogica one, was tested, compared or evaluated for efficacy or tolerability, and no conclusion is drawn about any individual brand. Disclosure, verbatim from the Footnotes: 'The authors report no relevant conflicts of interest.' Note that this paper is NOT returned by a PubMed search for 'Dermalogica' — the brand appears only in the product table, which PubMed does not index. Every figure above was re-checked against the PMC full text on 2 August 2026.